Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug...

|By:, SA News Editor

Synta Pharmaceuticals (SNTA +2.8%) gains after saying a study of ganetespib, its lead drug candidate, showed positive results as a treatment for oncologic indications, including a reduced rate of ocular toxicity. SNTA's primary research focus is on treatments for severe conditions such as cancer and chronic inflammatory diseases.